The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC.
 
Sanne Huijberts
No Relationships to Disclose
 
Jan H. M. Schellens
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Sirtex Medical
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche; Merck; Sirtex Medical
Speakers' Bureau - Sirtex Medical
Research Funding - Amgen (Inst); Novartis (Inst)
 
Marc Peeters
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Genentech; Merrimack; MolecularMatch; Roche; Sanofi; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; Lilly; Merck KGaA; Servier; Sirtex Medical
Speakers' Bureau - Celgene; Merck KGaA; Sirtex Medical
Research Funding - Merck KGaA (Inst); Pfizer (Inst); Sirtex Medical (Inst)
 
Jayesh Desai
Honoraria - Amgen; GlaxoSmithKline; Novartis
Consulting or Advisory Role - Amgen; Bionomics; Lilly; Novartis; Plexxikon
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Lilly; Merck Serono; Roche
Research Funding - Bayer; Roche
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)
 
Kati Maharry
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
 
Ashwin Gollerkeri
Employment - Array BioPharma; Pfizer
Stock and Other Ownership Interests - Array BioPharma
Patents, Royalties, Other Intellectual Property - Yale University (I)
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda